Projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry. Savings were $124.5 billion under an upper-bound scenario.
Kenneth Finegold, PhD
Advertisement
Articles by Kenneth Finegold, PhD
Advertisement
Latest Updated Articles
- Projected US Savings From Biosimilars, 2021-2025
January 3rd 2022
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
2
Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care
3
ICER Draft Flags High Cost of New Hypertension Drug Class
4
GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis
5